



# TuBerculosis Vaccine Initiative

## Symposium programme:

### “TB Vaccines: Global Collaboration and Recent Advances in the Field”

Tuesday afternoon 29<sup>th</sup> January 2019

#### Programme

13.50 – 14.00 *Photo whole group outside in front of the Maison des Congres*

14.00 - 14.05 Opening and Welcome - Nick Drager, TBVI, the Netherlands

#### **Global collaboration**

- 14.05-14.25 TBVAC2020: advances in the TB vaccine field - Ann Rawkins, PHE\_United Kingdom
- 14.25-14.45 BMGF TB vaccine programme – strategic directions and current activities – Willem Hanekom, (by Anne Kasmar), BMGF, United States [presentation Anne Kasmar](#)
- 14.45-15.05 Gates MRI Strategic Direction and Current TB Vaccine Activities - Penny Heaton GMRI, United States [presentation Penny Heaton](#)
- 15.05-15.25 NIAID strategic plan for TB research and current activities related to TB vaccines Katrin Eichelberg, NIH, United States [presentation Katrin Eichelberg](#)
- 15.25-15.40 Towards Horizon Europe – Hannu Laang, EC, Belgium [presentation Hannu Laang](#)
- 15.40-16.00 A new strategy for the Global HIV Vaccine Enterprise – facilitating solutions to complex challenges in HIV vaccine development and roll out, Birgit Poniatowski, International AIDS Society, Switzerland [presentation Birgit Poniatowski](#)
- 16.00-16.15 Future perspectives for TB vaccine development - Ole Olesen, EDCTP, The Netherlands [presentation Ole Olesen](#)
- 16.15-16.35 Introducing VALIDATE: A Global Challenges Research Fund network in vaccine R&D for complex intracellular pathogens, Helen McShane, UOXF, United Kingdom [presentation Helen McShane](#)

16.35-17.00 *Coffee/Tea – Maison des Congres*

***TB treatment and vaccines***

17.00-17.20 Preferred product characteristics for a therapeutic TB vaccine – Barry Walker, TBVI, the Netherlands [presentation Barry Walker](#)

17.20-17.35 New TB drug regimes and prospects for therapeutic vaccines and adjunct host-directed therapy, Frank Cobelens, AIGHD, the Netherlands [presentation Frank Cobelens](#)

***The TB vaccine pipeline***

17.35-17.50 Preferred Product Characteristics for a new TB vaccine –Johan Vekemans, WHO, Switzerland [presentation Johan Vekemans](#)

17.50-18.10 TB vaccine pipeline and Pathway to TB vaccines – Georges Thiry, TBVI, the Netherlands [presentation Georges Thiry](#)

18.10 -18.30 Efficacy trials of M72/AS01E and H4/BCG revaccination - Key takeaways – Ann Ginsberg- IAVI, United States

19.00 – 20.00 *Reception (Eurotel)*

20.00 *Dinner - Restaurant Eurotel*